Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies.

Deverka PA, Schully SD, Ishibe N, Carlson JJ, Freedman A, Goddard KA, Khoury MJ, Ramsey SD.

Genet Med. 2012 Jul;14(7):656-62. Erratum in: Genet Med. 2013 Jan;15(1):91.

2.

Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.

Esmail LC, Roth J, Rangarao S, Carlson JJ, Thariani R, Ramsey SD, Veenstra DL, Deverka P.

Genet Med. 2013 Feb;15(2):115-22. doi: 10.1038/gim.2012.103. Epub 2012 Oct 4.

3.
4.

Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2009 Jan;11(1):35-41. doi: 10.1097/GIM.0b013e31818fa2ff.

5.

Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.

Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine DA, Lau J.

Evid Rep Technol Assess (Full Rep). 2007 May;(150):1-180. Review.

6.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
7.

Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners.

Maradiegue A, Jasperson K, Edwards QT, Lowstuter K, Weitzel J.

J Am Acad Nurse Pract. 2008 Feb;20(2):76-84. doi: 10.1111/j.1745-7599.2007.00282.x. Review.

PMID:
18271762
8.

Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening.

Kilambi V, Johnson FR, González JM, Mohamed AF.

Value Health. 2014 Dec;17(8):838-45. doi: 10.1016/j.jval.2014.09.001. Epub 2014 Nov 6.

9.

Cancer diagnostics: decision criteria for marker utilization in the clinic.

Taube SE, Jacobson JW, Lively TG.

Am J Pharmacogenomics. 2005;5(6):357-64. Review.

PMID:
16336001
10.

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.

Westwood M, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, Misso K, Severens J, Kleijnen J.

Health Technol Assess. 2014 May;18(32):1-166. doi: 10.3310/hta18320. Review.

11.

Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer.

Manne SL, Chung DC, Weinberg DS, Vig HS, Catts Z, Cabral MK, Shannon K, Meropol NJ.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2110-7.

12.

Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.

Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA.

Ann Intern Med. 2011 Jul 19;155(2):69-79. doi: 10.7326/0003-4819-155-2-201107190-00002.

13.

Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.

Bellcross CA, Bedrosian SR, Daniels E, Duquette D, Hampel H, Jasperson K, Joseph DA, Kaye C, Lubin I, Meyer LJ, Reyes M, Scheuner MT, Schully SD, Senter L, Stewart SL, St Pierre J, Westman J, Wise P, Yang VW, Khoury MJ.

Genet Med. 2012 Jan;14(1):152-62. doi: 10.1038/gim.0b013e31823375ea. Epub 2011 Oct 27.

14.

When and how to perform genetic testing for inherited colorectal cancer syndromes.

Lynch PM.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1577-83. Review.

PMID:
24335689
15.

Prediction of Lynch syndrome in consecutive patients with colorectal cancer.

Green RC, Parfrey PS, Woods MO, Younghusband HB.

J Natl Cancer Inst. 2009 Mar 4;101(5):331-40. doi: 10.1093/jnci/djn499. Epub 2009 Feb 24.

PMID:
19244167
16.

Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.

Shi C, Washington K.

Am J Clin Pathol. 2012 Jun;137(6):847-59. doi: 10.1309/AJCPI83DINULUJNI.

PMID:
22586043
17.

[Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].

Schneider R, Schneider C, Büttner R, Reinacher-Schick A, Tannapfel A, Fürst A, Rüschoff J, Jakobeit C, Royer-Pokora B, Möslein G.

Zentralbl Chir. 2015 Dec;140(6):591-9. doi: 10.1055/s-0034-1368480. Epub 2014 Nov 5. Review. German.

PMID:
25372301
18.

Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.

Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, Roa BB, Wenstrup RJ, Hartman AR, Syngal S.

Gastroenterology. 2015 Sep;149(3):604-13.e20. doi: 10.1053/j.gastro.2015.05.006. Epub 2015 May 14.

19.

[Colorectal cancer: when and how to look for hereditary nonpolyposis colorectal neoplasm syndrome?].

Jaïs P.

Gastroenterol Clin Biol. 1999 Feb;23(2):284-6. French. No abstract available.

PMID:
10353029
20.

Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.

Tresallet C, Brouquet A, Julié C, Beauchet A, Vallot C, Ménégaux F, Mitry E, Radvanyi F, Malafosse R, Rougier P, Nordlinger B, Laurent-Puig P, Boileau C, Emile JF, Muti C, Penna C, Hofmann-Radvanyi H.

Int J Cancer. 2012 Mar 15;130(6):1367-77. doi: 10.1002/ijc.26144. Epub 2011 Jul 25.

Supplemental Content

Support Center